A University of Houston researcher has reported a 98.7-percent rate of accuracy for a method pioneered by his lab to identify cancers at their earliest stages. Photo via Getty Images

Could detecting cancer one day be as easy as taking a blood test? Wei-Chuan Shih, a University of Houston researcher and Cullen College of Engineering professor of electrical and computer engineering, has reported a 98.7-percent rate of accuracy for a method pioneered by his lab to identify cancers at their earliest stages.

The technology combines Shih’s own PANORAMA (PlAsmonic NanO-apeRture lAbel-free iMAging) with fluorescent imaging to view nanometer-sized membrane sacs, called extracellular vesicles or EVs. EVs carry different types of cargo, including proteins, nucleic acids and metabolites, throughout the bloodstream.

“We observed differences in small EV numbers and cargo in samples taken from healthy people versus people with cancer and are able to differentiate these two populations based on our analysis of the small EVs,” reports Shih, in Nature Communications Medicine. “The findings came from combining two imaging methods – our previously developed method PANORAMA and imaging of fluorescence emitted by small EVs—to visualize and count small EVs, determine their size and analyze their cargo.”

Shih introduced PANORAMA in 2020. The technology uses a glass side covered with gold nano discs that allows users to monitor changes in the transmission of light as well as determine the characteristics of nanoparticles as small as 25 nanometers in diameter. For the new publication, Shih and his team just had to count the number of small EVs in order to detect cancer.

“Using a cutoff of 70 normalized small EV counts, all cancer samples from 205 patients were above this threshold except for one sample, and for healthy samples, from 106 healthy individuals, all but three were above this cutoff, giving a cancer detection sensitivity of 99.5% and specificity of 97.3%,” says Shih.

The team was able to report 100-percent accuracy with further testing that analyzed two independent sets of samples from stage I-IV or recurrent leiomyosarcoma/gastrointestinal stromal tumors and early-and-late-stage cholangiocarcinoma combined with healthy samples.

Shih and collaborator Steven H. Lin have founded Seek Diagnostics with the goal of commercializing the technology that they’ve innovated. In 2022, the duo joined the Texas Medical Center Innovation's cancer-focused accelerator.


Wei-Chuan Shih is a professor of electrical and computer engineering at the University of Houston's Cullen College of Engineering. Photo via UH.edu

Mark Clarke (left) and Wei-Chuan Shih were named among the National Academy of Inventors' inaugural class of senior members. Courtesy of the University of Houston

2 UH scientists receive prestigious national recognition for fostering innovation

top of the class

Two researchers at the University of Houston have been named to the inaugural class of senior members for the National Academy of Inventors. The new distinction recognizes the honorees for fostering innovation and educating and mentoring future innovators — as well as their contribution to science and technology.

The two UH honorees are Mark Clarke, associate provost for faculty development and faculty affairs, and Wei-Chuan Shih, associate professor of electrical and computer engineering. Both will be recognized at the eighth annual NAI meeting in Houston this April, a release from UH says.

"Dr. Clarke and Dr. Shih both have impressive records of producing impactful intellectual property and spurring innovation that is pertinent to the Houston region," Amr Elnashai, vice president of research and technology at UH, says in the release. "Their further efforts, including helping UH faculty commercialize technologies as well as working with graduate and undergraduate students to boost their entrepreneurial efforts, are a critical contribution to building the region's innovation ecosystem."

NAI named 65 total scientists from 37 universities as senior members. The scientists have been named on over 1,100 patents issued in the United States. Ten other Texas scientists made the inaugural class, representing Texas Tech university, Texas A&M University, Baylor College of Medicine, and University of Texas at Arlington.

The organization also has a fellowship program, in which UH has 12 current fellows.

Clarke has been at UH for over a decade and previously held the position of associate vice chancellor/vice president for technology transfer at the UH Division of Research, where he oversaw a portfolio of 360 technology patents, according to the release. Clarke has 13 patents to his name and previously worked at two startups — both commercialized technologies Clarke developed in his tenure at NASA then UH.

UH's other senior NIA member, Shih, has been granted 11 patents in the US. His NanoBioPhotonics Group has developed a number of sensing and imaging technologies and devices for biomedicine and environmental testing, among other fields. Shih, who has been at the university for over nine years, created a startup with a group of students called DotLens. The company produced and distributed lenses that could be used to convert a smartphone into a microphone.

A few months ago, a Houston scientist received international recognition when he

won the Nobel Prize for the cancer research he did for the University of Texas MD Anderson Cancer center. Jim Allison won for his work in launching an effective new way to attack cancer by treating the immune system rather than the tumor.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.